<DOC>
	<DOCNO>NCT01939132</DOCNO>
	<brief_summary>Psoriatic arthritis heterogeneous chronic inflammatory disorder involve joint , tendon sheath , entheses , axial skeleton well skin nail . This open-label trial H.P . Acthar Gel ( 80 units/1mL ) Subcutaneous injection administer twice weekly . To evaluate sign symptom psoriatic arthritis 12 week , include American College Rheumatology 20 , Clinical Disease Activity Index , Disease Activity Index 28 , Dactylitis adverse event .</brief_summary>
	<brief_title>Protocol H.P . Acthar Gel Moderately Severely Active Psoriatic Arthritis</brief_title>
	<detailed_description>The subject study adult men woman age 18-75 year age time screen chronic , moderately-to-severely active PsA meeting ACR criterion .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Psoriatic</mesh_term>
	<mesh_term>Adrenocorticotropic Hormone</mesh_term>
	<criteria>1 . In opinion investigator , must adequate reading write ability ( native language ) subject comprehend complete informed consent , protocolrelated assessment . 2 . Age 1875 year time screen 3 . Written inform consent locally require authorization ( e.g . HIPAA ) obtain subject prior performing protocolrelated procedure , include screen evaluation . 4 . Subject diagnosis psoriatic arthritis ( Classification Psoriatic Arthritis ( CASPAR ) criterion ) least 6 month . 5 . Subject must &gt; 6 tender &gt; 6 swollen joint count screening . 6 . Subject must &gt; 30 minute morning joint stiffness . 7 . For subject receive nonsteroidal antiinflammatory drug ( NSAIDs ) ( include PRN use ) : subject must stable dose &gt; 4 week prior initiation H.P . Acthar Gel . 8 . For subject receive DiseaseModifying AntiRheumatic Drug ( DMARD ) Biologic agent : subject receive treatment &gt; 8 week , stable &gt; 4 week prior initiation H.P . Acthar Gel . 9 . For subject receive oral corticosteroid : subject must stable dose ( exceed equivalent 10mg prednisone per day ) &gt; 2 week prior initiation H.P . Acthar Gel . 10 . Subject negative test tuberculosis within 6 month initiate H.P . Acthar Gel define either : Negative purified protein derivative ( PPD ) Negative Quantiferon test , Negative chest xray 11 . Females childbearing potential must use effective method birth control avoid pregnancy screen 60 day final dose H.P . Acthar Gel unless surgically sterile ( i.e . bilateral tubal ligation , bilateral oophorectomy , complete hysterectomy ) , sterile male partner , &gt; 1 year postmenopausal practice abstinence ( sexual intercourse ) : 1 . Subject plan surgical intervention baseline week 24 evaluation . 2 . Subject concurrent medical condition uncontrolled , clinically significant systemic disease ( eg , renal failure , congestive heart failure , uncontrolled hypertension , primary adrenocortical insufficiency adrenocortical hyperfunction , peptic ulcer sensitivity proteins porcine origin ) 3 . Subject diagnosis scleroderma , osteoporosis , fungal infection ocular herpes simplex 4 . History type malignancy &lt; 5 year enrollment study ( apart basal cell carcinoma ) 5 . Any live attenuate vaccine within 4 week prior sign inform consent form ( administration kill vaccine acceptable ) 6 . Subject active tuberculosis 7 . Any know history allergy reaction component H.P . Acthar Gel 8 . Known history primary immunodeficiency underlie condition human immunodeficiency virus ( HIV ) infection . 9 . Employees clinical study site individual involve conduct study immediate family member individual 10 . Concurrent enrollment clinical study investigational product within 4 week prior enrollment study . 11 . Lactating pregnant female female intend become pregnant anytime initiation screen 60 day post last dose H.P . Acthar Gel</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>Psoriatic Arthritis</keyword>
	<keyword>ACTH</keyword>
	<keyword>Acthar</keyword>
</DOC>